Filing Flows › Health Care › CG Oncology (CGON)
CG Oncology (CGON) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · CG Oncology (CGON) Q3 2026 earnings results →
Q3 2026 Revenue down 4% year over year to $1.6M
CG Oncology made $1.6M in Q3 2026 (-4% Y/Y). Operating margin n/m, net loss $56.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.6M in Q3 2026, down 4% year over year and up 39% from the previous quarter.
Operating costs exceeded revenue by $63.2M, an operating margin of -3943.2%. Total costs grew 23% against a revenue fall of 4%. The fastest-growing cost line was Cost of revenue (+69%). The quarter ended with a net loss of $56.9M, narrower than the previous quarter's $79.1M loss.
Operating cash flow was −$47.7M. Non-cash charges added back $1.2M of depreciation and amortization and $8.5M of share-based compensation. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$48.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $1.6M | -4% | n/m | −$56.9M | −$47.7M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $1.2M | — | n/m | −$79.1M | −$46.4M |
| Q1 2026 | 10-Q | May 8, 2026 | $1.1M | 21× | n/m | −$60.2M | −$56.9M |
| Q4 2025 | 10-K | Feb 27, 2026 | $2.3M | +409% | n/m | −$41.3M | −$36.2M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $1.7M | 39× | n/m | −$43.8M | −$38.9M |
| Q1 2025 | 10-Q | May 13, 2025 | $52K | -90% | n/m | −$34.5M | −$29.3M |
| Q4 2024 | 10-K | Mar 28, 2025 | $456K | 456× | n/m | −$31.8M | −$20.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
In its own words, from its 8-K, filed Aug 6, 2026.
CG Oncology against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -4% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CGON CG Oncology | Q3 2026 | $1.6M | -4% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: CG Oncology 10-Q on SEC EDGAR · CIK 1991792 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns CGON and who is buying
More on CGON
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q1 2025 results · Q4 2024 results